CD4 and cancer: On multivariate analysis, grade (HR 2.47, 95% CI 1.37–4.46, P<0.01) and percentage CD4+ (HR 4.44, 95% CI 1.87–10.57, P<0.001) were independently associated with cancer-specific survival.